Cereno Scientific
7,1 SEK -3,79%3 investorer følger denne virksomhed
Cereno Scientific is active in biotechnology. The company specializes in drug development for common and rare cardiovascular diseases. The main drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension (PAH), as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. The head office is in Mölndal with offices also in North America.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
CRNO B
Daglig lav / høj pris
6,64 / 7,37
SEK
Markedsværdi
2 mia. SEK
Aktieomsætning
21,19 mio. SEK
Volumen
3 mio.
Seneste videoer
Finanskalender
Delårsrapport
21.11.2024
Årsrapport
25.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Avanza Pension | 20,7 % | 20,2 % |
Pareto Securities AS | 5,6 % | 5,5 % |
Dory Gevryie | 1,6 % | 1,5 % |
Andreas Eljegard | 1,4 % | 1,3 % |
Jan Butt | 1,4 % | 1,3 % |
Nordnet Pensionsförsäkring AB | 1,2 % | 1,1 % |
Mårten Lundberg | 0,8 % | 0,8 % |
Niklas Borgquist | 0,7 % | 0,7 % |
Claes Sverker Jern | 0,6 % | 1,3 % |
Olof Niklas Bergh | 0,2 % | 0,9 % |
ViserAlle indholdstyper
Save the date for Cereno Scientific's Capital Markets Day on October 17, 2024
Cereno Scientific signs agreement with Fluidda, to evaluate the impact of its HDAC inhibitor CS1 on reverse remodeling of pulmonary vessels in patients with PAH
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools